INDV — Indivior PLC Stock Price, Chart & AI Report

Positive May 30, 2026 • 20:01 UTC The Motley Fool • Jonathan Ponciano

What to Know About This Fund's $74.8 Million Indivior Sale

Divisadero Street Capital Management sold 2.26 million shares of Indivior (INDV) for approximately $74.76 million in Q1 2026, reducing its stake to 521,083 shares. The sale appears to be profit-taking after the stock surged nearly 200% over the past year. Despite the fund's exit, Indivior's fundamentals remain strong with Q1 revenue up 19% year-over-year to $317 million and SUBLOCADE sales jumping 32% to $232 million, prompting management to raise 2026 guidance.

INDV CLS CELH fund sale profit-taking opioid addiction treatment buprenorphine SUBLOCADE

Sentiment note

Despite the fund's partial exit, Indivior demonstrates strong business momentum with 19% revenue growth, 32% SUBLOCADE sales growth, doubled adjusted EBITDA to $164 million, and raised 2026 guidance to $1.29 billion in revenue. The sale is characterized as profit-taking rather than a sign of business deterioration, and the company's underlying fundamentals remain intact with over 500,000 patients on SUBLOCADE.

Positive Apr 24, 2026 • 15:00 UTC GlobeNewswire Inc. • Indivior Pharmaceuticals, Inc.

Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder

Indivior presented new real-world data at the ASAM 2026 Annual Conference demonstrating that SUBLOCADE (monthly injectable buprenorphine) accounts for the smallest proportion of non-fatal and fatal overdose events compared to other medications for opioid use disorder. The company also presented findings from the ROUTE Study showing that remission from OUD correlates with improved quality of life, lower craving, and better functional outcomes beyond abstinence alone.

INDV opioid use disorder buprenorphine SUBLOCADE medication-assisted treatment overdose prevention remission clinical outcomes

Sentiment note

The company presented favorable clinical data showing SUBLOCADE has superior overdose prevention outcomes compared to other MOUD treatments and no treatment. The ROUTE Study findings support remission as a meaningful treatment endpoint with improved quality of life metrics. With over 500,000 patients prescribed their long-acting injectable therapy, the data reinforces market position and clinical efficacy, supporting continued adoption and business growth.

Positive Apr 9, 2026 • 11:00 UTC GlobeNewswire Inc. • Na

Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th

Indivior Pharmaceuticals (INDV) announced it will report first quarter 2026 financial results on April 30, 2026, followed by a live webcast presentation at 8:00 a.m. EDT with CEO Joe Ciaffoni and leadership team. The company highlighted a cost impact model showing its monthly injectable buprenorphine treatment (SUBLOCADE) may reduce staffing burdens and costs in correctional facilities compared to other opioid use disorder medications.

INDV financial results Q1 2026 opioid use disorder buprenorphine SUBLOCADE correctional facilities cost reduction

Sentiment note

The company is presenting a cost impact model demonstrating potential benefits of its SUBLOCADE product in reducing staffing burdens and costs in correctional facilities, which positions the drug favorably against competitors and suggests potential for market expansion and revenue growth in the opioid use disorder treatment space.

Neutral Mar 13, 2026 • 00:30 UTC GlobeNewswire Inc. • Na

Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering

Indivior Pharmaceuticals priced a $450 million offering of 0.625% convertible senior notes due 2031, upsized from the initially announced $400 million. The notes have a conversion price of approximately $41.66 per share (35% premium to market price) and will mature on March 15, 2031. Net proceeds of approximately $437.7 million will be used to repay existing debt ($239 million plus $102 million cash on hand), repurchase approximately 2.4 million shares ($75 million), and fund general corporate purposes.

INDV convertible notes debt offering share repurchase opioid use disorder treatment capital structure qualified institutional buyers

Sentiment note

The offering represents a capital raise and debt refinancing activity, which is operationally neutral. While the company is raising capital and refinancing debt (generally positive for liquidity), the concurrent share repurchase at market prices and the relatively low coupon rate (0.625%) suggest the company is managing its capital structure pragmatically. No material business developments or operational changes are announced that would warrant a more positive or negative sentiment.

Neutral Mar 12, 2026 • 11:00 UTC GlobeNewswire Inc. • Na

Indivior Announces Proposed Convertible Senior Notes Offering

Indivior Pharmaceuticals announced its intention to offer $400 million in convertible senior notes due 2031 in a private placement to qualified institutional buyers. The company plans to use approximately $239 million of net proceeds to repay existing term loan and revolving credit facility borrowings, up to $75 million for share repurchases, and the remainder for general corporate purposes. The notes will be convertible into common stock under specified conditions and redeemable after March 2029.

INDV convertible notes debt offering capital structure share repurchase opioid use disorder treatment SUBLOCADE qualified institutional buyers

Sentiment note

The offering is a standard debt financing activity used to refinance existing debt and fund share repurchases. While the company demonstrates financial activity and access to capital markets, the announcement itself is transactional in nature without material operational or strategic developments. The concurrent share repurchase could be viewed as management confidence, but the overall tone is procedural rather than indicating positive or negative business momentum.

Positive Jan 28, 2026 • 12:00 UTC GlobeNewswire Inc. • Na

Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ

Indivior Pharmaceuticals announced it will report its Q4 and full-year 2025 financial results on February 26, 2026, followed by a leadership webcast. The company also completed its redomiciliation from the United Kingdom to the United States and provided 2026 financial guidance projecting total net revenue between $1,125-$1,195 million, with SUBLOCADE net revenue expected at $905-$945 million.

INDV financial results webcast redomiciliation opioid use disorder SUBLOCADE revenue guidance long-acting injectable

Sentiment note

The company is providing specific revenue guidance for 2026 and has successfully completed its redomiciliation to the US, which are strategic corporate actions. The guidance range suggests stable to growing revenue expectations, and the company maintains its market leadership position in OUD treatments with SUBLOCADE as a key revenue driver.

Positive Oct 30, 2025 • 18:18 UTC The Motley Fool • Lee Samaha

Here's Why Indivior Stock Soared 15% Today

Indivior reported strong Q3 results, upgrading full-year guidance for Sublocade sales to $825-$845 million. The company is executing a three-phase growth strategy focused on increasing U.S. sales and achieving expense savings.

INDV Sublocade opioid use disorder pharmaceutical sales growth restructuring

Sentiment note

Company showed strong sales growth (7% increase in Sublocade sales), upgraded financial guidance, and outlined a strategic plan for future expansion with planned expense savings and potential acquisitions

Neutral Jul 25, 2025 • 14:51 UTC GlobeNewswire Inc. • Researchandmarkets.Com

Cannabis Use Disorder (CUD) Pipeline Market Research Report 2025 Featuring Aelis Farma, Anebulo Pharmaceuticals, and Indivior

A comprehensive market research report analyzing the Cannabis Use Disorder pipeline, featuring over 5 companies developing novel treatments for addressing CUD challenges.

ANEB INDV Cannabis Use Disorder CUD pipeline drug development clinical trials

Sentiment note

Noted as a key player with a pipeline product INDV-5004, but no specific performance details provided

Positive Jun 5, 2025 • 05:00 UTC GlobeNewswire Inc. • N/A

Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference

Addex Therapeutics announced that it will present preclinical data on its GABAB positive allosteric modulator cough program at the American Cough Conference. The company's lead drug candidate is ready to start IND enabling studies.

ADXN INDV Addex Therapeutics GABAB cough positive allosteric modulator

Sentiment note

The article mentions that Addex's partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies, suggesting a positive collaboration between the two companies.

Positive Apr 28, 2025 • 17:00 UTC GlobeNewswire Inc. • Delveinsight

Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsight

The substance use disorder market is expected to grow between 2025 and 2034, driven by greater awareness, the introduction of new therapies, and ongoing research and development efforts. The report covers the market assessment of Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder.

ADIL CMND BTAI INDV substance use disorder alcohol use disorder cocaine use disorder opioid use disorder

Sentiment note

The company's INDV-2000 is listed as an investigational therapy for opioid use disorder.

Negative Oct 10, 2024 • 13:28 UTC Benzinga • Benzinga Editor

Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details

Indivior cuts its FY24 revenue guidance due to lower-than-expected SUBLOCADE revenue amid competition from a competing injectable product, leading to a decline in the company's stock price.

INDV Indivior SUBLOCADE revenue guidance competition

Sentiment note

Indivior cut its FY24 revenue guidance due to lower-than-expected SUBLOCADE revenue, which was impacted by competition from a competing injectable product. This led to a decline in the company's stock price.

Negative Sep 30, 2024 • 23:29 UTC GlobeNewswire Inc. • N/A

Indivior PLC Investors: Please contact the Portnoy Law Firm to recover your losses. October 1, 2024 Deadline to file Lead Plaintiff Motion

Indivior PLC investors are advised to contact the Portnoy Law Firm to recover losses from alleged corporate wrongdoing during the class period of February 22, 2024 to July 8, 2024. The complaint claims the company exaggerated its ability to predict the impact of legislation, inflated financial outlooks, and made misleading statements about its business and prospects.

INDV Indivior PLC Portnoy Law Firm class action corporate wrongdoing

Sentiment note

The article suggests that Indivior PLC made misleading statements and exaggerated its financial outlook, leading to losses for investors during the class period. This indicates a negative sentiment towards the company.